Achilles Therapeutics plc (ACHL)

NASDAQ: ACHL · IEX Real-Time Price · USD
1.71
-0.04 (-2.29%)
Dec 5, 2022 4:00 PM EST - Market closed
-2.29%
Market Cap 71.64M
Revenue (ttm) n/a
Net Income (ttm) -65.35M
Shares Out 39.31M
EPS (ttm) 6.35
PE Ratio 0.27
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,863
Open 1.75
Previous Close 1.75
Day's Range 1.71 - 1.85
52-Week Range 1.58 - 5.65
Beta n/a
Analysts Buy
Price Target 15.91 (+830.4%)
Earnings Date Nov 8, 2022

About ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carci... [Read more]

Industry Biotechnology
IPO Date Mar 31, 2021
Employees 242
Stock Exchange NASDAQ
Ticker Symbol ACHL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ACHL stock is "Buy." The 12-month stock price forecast is 15.91, which is an increase of 830.41% from the latest price.

Price Target
$15.91
(830.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive...

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -

4 days ago - GlobeNewsWire

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using P...

- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches - - US patent is...

1 week ago - GlobeNewsWire

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 -

3 weeks ago - GlobeNewsWire

What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne...

1 month ago - Zacks Investment Research

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal N...

Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets

1 month ago - GlobeNewsWire

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 -

3 months ago - GlobeNewsWire

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platform €4 million ($4.2 million) research and innovation award for co...

4 months ago - GlobeNewsWire

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...

5 months ago - GlobeNewsWire

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...

5 months ago - GlobeNewsWire

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma -

6 months ago - GlobeNewsWire

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Ini...

- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review -

6 months ago - GlobeNewsWire

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...

7 months ago - GlobeNewsWire

Achilles Therapeutics to Present at Upcoming Conferences

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...

7 months ago - GlobeNewsWire

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse

Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy KING OF PRUSSIA, Pa. , April 12, 2022 /PRNewswire/ --The Center for Breakthrough Medicines (CBM) announced today a...

7 months ago - PRNewsWire

Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development –

7 months ago - GlobeNewsWire

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder -

8 months ago - GlobeNewsWire

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

8 months ago - GlobeNewsWire

Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 -

9 months ago - GlobeNewsWire

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

Internationally recognized experts bring extensive scientific and clinical research expertise in cancer immunology and immunotherapy Internationally recognized experts bring extensive scientific and cli...

9 months ago - GlobeNewsWire

Achilles Therapeutics Provides Business Update and Outlook for 2022

LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...

10 months ago - GlobeNewsWire

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...

11 months ago - GlobeNewsWire

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...

11 months ago - GlobeNewsWire

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precisi...

-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing-

11 months ago - GlobeNewsWire

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating th...

- Conference call and webcast scheduled for today at 8:30am ET / 1:30pm UK - - Conference call and webcast scheduled for today at 8:30am ET / 1:30pm UK -

1 year ago - GlobeNewsWire

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T ...

Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM enables di...

1 year ago - Accesswire